prognostic signature

Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.

ASCO said MammaPrint should be used to inform decisions on withholding chemotherapy for these clinically high risk, HR-positive, HER2-negative breast cancers.

A small study of prostate cancers from African American and European American men uncovered ancestry-associated splicing with apparent ties to tumor aggressiveness and resistance.

Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.

New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.

A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic. 

The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.

An international team of researchers examined differential gene expression in blood samples from patients infected during the West African outbreak.

A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.

Researchers uncovered snoRNA differences in tumors from breast cancer cases with better or worse overall survival or recurrence-free survival.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.